140 related articles for article (PubMed ID: 38334173)
1. Use of therapeutic plasma exchange to remove lipoprotein X in a patient with vanishing bile duct syndrome presenting with cholestasis, pseudohyponatremia, and hypercholesterolemia: A case report and review of literature.
Jung Y; Nelson HA; Lin DM
J Clin Apher; 2024 Feb; 39(1):e22105. PubMed ID: 38334173
[TBL] [Abstract][Full Text] [Related]
2. Extreme hypercholesterolemia presenting with pseudohyponatremia - a case report and review of the literature.
Hussain I; Ahmad Z; Garg A
J Clin Lipidol; 2015; 9(2):260-4. PubMed ID: 25911084
[TBL] [Abstract][Full Text] [Related]
3. Low-density lipoprotein apheresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2007; 7(5):1-101. PubMed ID: 23074505
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein-X in patients with cirrhosis: its relationship to cholestasis and hypercholesterolemia.
Sörös P; Böttcher J; Maschek H; Selberg O; Müller MJ
Hepatology; 1998 Nov; 28(5):1199-205. PubMed ID: 9794902
[TBL] [Abstract][Full Text] [Related]
5. Pseudohyponatremia in acute liver disease.
Vo H; Gosmanov AR; Garcia-Rosell M; Wall BM
Am J Med Sci; 2013 Jan; 345(1):62-4. PubMed ID: 23232812
[TBL] [Abstract][Full Text] [Related]
6. Management of lipoprotein-X accumulation in severe cholestasis by semi-selective LDL-apheresis.
Franceschini G; Busnach G; Chiesa G; Sirtori CR
Am J Med; 1991 May; 90(5):633-8. PubMed ID: 2029022
[TBL] [Abstract][Full Text] [Related]
7. Pseudohyponatremia Secondary to Hypercholesterolemia in the Setting of Intrahepatic Cholestasis due to Metastatic Liver Disease: A Case Report and Review of the Literature.
Pourafkari L; Cavalieri C; Yavari SK; Nader ND
Acta Med Acad; 2022 Aug; 51(2):128-131. PubMed ID: 36318005
[TBL] [Abstract][Full Text] [Related]
8. Severe hypercholesterolemia mediated by lipoprotein X in patients with chronic graft-versus-host disease of the liver.
Turchin A; Wiebe DA; Seely EW; Graham T; Longo W; Soiffer R
Bone Marrow Transplant; 2005 Jan; 35(1):85-9. PubMed ID: 15531904
[TBL] [Abstract][Full Text] [Related]
9. Role of lipoprotein-X in the pathogenesis of cholestatic hypercholesterolemia. Uptake of lipoprotein-X and its effect on 3-hydroxy-3-methylglutaryl coenzyme A reductase and chylomicron remnant removal in human fibroblasts, lymphocytes, and in the rat.
Walli AK; Seidel D
J Clin Invest; 1984 Sep; 74(3):867-79. PubMed ID: 6470142
[TBL] [Abstract][Full Text] [Related]
10. Plasma exchange for the management of refractory pruritus of cholestasis: A report of three cases and review of literature.
Chkheidze R; Joseph R; Burner J; Matevosyan K
J Clin Apher; 2018 Jun; 33(3):412-418. PubMed ID: 28792089
[TBL] [Abstract][Full Text] [Related]
11. Multiple lipoprotein and electrolyte laboratory artifacts caused by lipoprotein X in obstructive biliary cholestasis secondary to pancreatic cancer.
Sivakumar T; Chaidarun S; Lee HK; Cervinski M; Comi R
J Clin Lipidol; 2011; 5(4):324-8. PubMed ID: 21784379
[TBL] [Abstract][Full Text] [Related]
12. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels.
Kroon AA; van't Hof MA; Demacker PN; Stalenhoef AF
Atherosclerosis; 2000 Oct; 152(2):519-26. PubMed ID: 10998482
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein-X fifty years after its original discovery.
Fellin R; Manzato E
Nutr Metab Cardiovasc Dis; 2019 Jan; 29(1):4-8. PubMed ID: 30503707
[TBL] [Abstract][Full Text] [Related]
14. Hypercholesterolemia due to lipoprotein-X manifesting as pseudohyponatremia in a patient with cholestasis.
Azad F; Mughaedh NA; Alloghbi A; Tawhari I
Proc (Bayl Univ Med Cent); 2023; 36(2):222-223. PubMed ID: 36876244
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein-X in cholestatic patients causes xanthomas and promotes foam cell formation in human macrophages.
Suzuki L; Hirayama S; Fukui M; Sasaki M; Hiroi S; Ayaori M; Terai S; Tozuka M; Watada H; Miida T
J Clin Lipidol; 2017; 11(1):110-118. PubMed ID: 28391876
[TBL] [Abstract][Full Text] [Related]
16. Case report: Unusual and extremely severe lipoprotein X-mediated hypercholesterolemia in extrahepatic pediatric cholestasis.
Colantuono R; Pavanello C; Pietrobattista A; Turri M; Francalanci P; Spada M; Vajro P; Calabresi L; Mandato C
Front Pediatr; 2022; 10():969081. PubMed ID: 35989999
[TBL] [Abstract][Full Text] [Related]
17. Role of plasma and liver cholesterol- and lipoprotein-metabolism determinants in LpX formation in the mouse.
Bravo I; Amigo L; Cohen DE; Nervi F; Rigotti A; Francone O; Zanlungo S
Biochim Biophys Acta; 2007 Jun; 1770(6):979-88. PubMed ID: 17399905
[TBL] [Abstract][Full Text] [Related]
18. Severe hypercholesterolemia mediated by lipoprotein X in a patient with cholestasis.
Phatlhane DV; Zemlin AE
Ann Hepatol; 2015; 14(6):924-8. PubMed ID: 26436366
[TBL] [Abstract][Full Text] [Related]
19. The lipid- and lipoprotein- [LDL-Lp(a)] apheresis techniques. Updating.
Stefanutti C; Morozzi C; Perrone G; Di Giacomo S; Vivenzio A; D'Alessandri G
G Chir; 2012; 33(11-12):444-9. PubMed ID: 23140934
[TBL] [Abstract][Full Text] [Related]
20. [Studies on the structure and metabolism of lipoprotein-X (LP-X), the abnormal plasmalipoprotein in cholestasis (author's transl)].
Seidel D
Klin Wochenschr; 1977 Jul; 55(13):611-23. PubMed ID: 197298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
